Vikas Lifecare share news and announcements
NSE: VIKASLIFEBSE: 542655Commercial Services & SuppliesSmall Cap
Formerly Vikas Multicorp
Last close ₹1.14down ₹0.01 (0.87%)BSE ₹1.14
Share price at the NSE close on 23 Oct 2026. Previous close ₹1.15.
52-week range of traded prices to 23 Oct 2026
₹1.05Low, 30 Mar 2026₹2.15High, 23 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹212 Cr2,160th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 28,67,32844.3% delivered
Vikas Lifecare share news and announcements
445 announcements, routine notices left out, newest first. Page 7 of 9.
Dec 2021
Nov 2021
Oct 2021
26 Oct · Corporate action
26 Oct · Corporate action
21 Oct · Board meeting
15 Oct · Results
14 Oct · Results
Sep 2021
27 Sep · Legal
Exchange has sought clarification from Vikas Lifecare Limited with respect to announcement dated 24-Sep-2021, regarding board meeting held on September 24, 2021. On basis of above the Company is required to clarify following - 1. Confirmation in compliance with SEBI Letter dated June 14, 2018 read alongwith NSE Circular dated June 20, 2018 (in case of appointment of directors); 2. Detailed Reasons for Resignation (resignation of independent director). The response of the Company is awaited.24 Sep · Board meeting
21 Sep · Updates
21 Sep · Updates
21 Sep · Updates
Aug 2021
28 Aug · Updates
27 Aug · Legal
Exchange has sought clarification from Vikas Lifecare Limited with respect to announcement dated 25-Aug-2021, regarding Outcome of Board meeting held on August 25, 2021. On basis of above the Company is required to clarify following: 1. Amendments to Memorandum and/or Articles of association of listed entity, in brief.2. Confirmation from the resigning director that there are no other material reasons other than provided3. Detailed Reasons for Resignation of director4. Details as per Annexure A of SEBI Circular CIR/CFD/CMD1/114/2019 dated October 18, 2019 w.r.t Resignation of statutory auditors from listed entitiesThe response of the Company is awaited.25 Aug · Board meeting
20 Aug · Legal
Exchange has sought clarification from Vikas Lifecare Limited for the quarter ended 30-Jun-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.10 Aug · Updates
Jul 2021
20 Jul · Legal
Exchange has sought clarification from Vikas Lifecare Limited with respect to announcement dated 19-Jul-2021, regarding proposal to acquire M/s Hydrolina Biotech Private Limited. On basis of above the Company is required to clarify following: 1. Name of the target entity, details in brief such as size, turnover etc;2. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";3. Cost of acquisition or the price at which the shares are acquired;4. Nature of consideration - whether cash consideration or share swap and details of the same;5. Percentage of shareholding / control acquired and / or number of shares acquired;The response of the Company is awaited.19 Jul · Board meeting
16 Jul · Board meeting
15 Jul · Legal
Exchange has sought clarification from Vikas Lifecare Limited with respect to announcement dated 14-Jul-2021, regarding 'Vikas Lifecare acquired 22.04% stake in Advik Laboratories Ltd'. On basis of above the Company is required to clarify following: 1. Name of the target entity, details in brief such as size, turnover etc;2. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";3. Cost of acquisition or the price at which the shares are acquired;The response of the Company is awaited.12 Jul · Legal
Exchange has sought clarification from Vikas Lifecare Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted -2. Financial results submitted is not as per format prescribed by SEBI -3. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.9 Jul · Board meeting
Jun 2021
29 Jun · Legal
Exchange has sought clarification from Vikas Lifecare Limited with respect to announcement dated 25-Jun-2021, regarding acquisition of a start-up Green life Agritech. On basis of above the Company is required to clarify following: 1. Name of the target entity, details in brief such as size, turnover etc;2. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";3. Brief details of any governmental or regulatory approvals required for the acquisition;4. Indicative time period for completion of the acquisition;5. Cost of acquisition or the price at which the shares are acquired;6. Nature of consideration - whether cash consideration or share swap and details of the same;7. Percentage of shareholding / control acquired and / or number of shares acquired;8. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief). The response of the Company is awaited.28 Jun · Updates
25 Jun · Board meeting
22 Jun · Updates